It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Entasis Therapeutics Holdings Inc (ETTX) USD0.001

Sell:$2.09 Buy:$2.10 Change: $0.10 (5.03%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Change: $0.10 (5.03%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
Change: $0.10 (5.03%)
Market closed |  Prices as at close on 18 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibacterial products to treat infections caused by multi-drug resistant Gram-negative bacteria. Its lead product candidate ETX2514 and its other product candidate ETX0282 inhibits bacterial resistance, b-lactamase enzyme. Its pipeline includes ETX2514UL, ETX0282CPDp, Zoliflodacin, and non-beta (b)-lactam inhibitors of the penicillin-binding proteins (NBP) Program. ETX2514SUL is a fixed-dose combination of ETX2514 with sulbactam, as a novel IV antibiotic with broad spectrum b-lactamase coverage. Zoliflodacin as a single dose, oral antibiotic monotherapy. ETX0282CPDP is an oral fixed-dose combination of ETX0282 with cefpodoxime proxetil. The Company is developing a class of antibiotics with its NBP program in which it is designing molecules for optimal activity against the penicillin-binding proteins (PBP) enzymes.

Contact details

35 Gatehouse Drive
United States
+1 (781) 8100120

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$73.13 million
Shares in issue:
37.31 million
United States
US dollar

Key personnel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.